Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EMN 2018

Measurable Residual Disease

View all
4:23
MRD in myeloma: the complementary role of imaging techniques
Elena Zamagni • 19 Apr 2018
2:45
Predicting long-term outcomes in myeloma: MRD
Philip McCarthy • 19 Apr 2018

Immunotherapy

View all
2:19
Novel avenues for MM treatment: CAR T-cells, venetoclax, induction & MRD
Nikhil Munshi • 19 Apr 2018
2:45
Monoclonal antibodies: the arsenal against R/R MM
Niels van de Donk • 19 Apr 2018

Transplantation

View all
2:02
Transplant trials in myeloma: EMN02 and BMT CTN 0702
Philip McCarthy • 19 Apr 2018
1:55
ASCT remains at the forefront of multiple myeloma therapy
Vittorio Montefusco • 19 Apr 2018

Smoldering Multiple Myeloma

View all
1:39
Therapeutic options for smoldering myeloma
Nicola Giuliani • 19 Apr 2018
1:16
Clinical significance of smoldering myeloma
Robert Kyle • 19 Apr 2018
The content of VJHemOnc is intended for healthcare professionals